The city of Savannah, Georgia, currently has 5 active clinical trials seeking participants for Alzheimer's Disease research studies.
A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)
NCT06721156
Recruiting
Researchers want to learn if giving MK-1167 (the study medicine) along with acetylcholinesterase inhibitor (AChEI) therapy can improve symptoms of Alzheimer's disease dementia (AD dementia), such as memory and mental activity. AD dementia is the most common type of dementia. AChEI therapy is the standard treatment for AD dementia. The goals of this study are to learn: * If at least one dose level (amount) of MK-1167 works to improve a person's memory and thinking compared to a placebo * About... Read More
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
05/08/2025
Locations: CenExel iResearch, LLC ( Site 0134), Savannah, Georgia
Conditions: Alzheimer Disease, Dementia
Register for Updates
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
NCT05026866
Recruiting
The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD). Approximately 800 additional participants will be enrolled in a 12-month addendum to assess safety of a different titration regimen.
Gender:
ALL
Ages:
Between 65 years and 80 years
Trial Updated:
05/08/2025
Locations: Meridian Clinical Research, LLC, Savannah, Georgia
Conditions: Alzheimer Disease
Register for Updates
A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease
NCT06538116
Recruiting
The main purpose of this study is to look at how safe the study drug (mevidalen) is and whether it works to alleviate symptoms when given to people with mild to moderate Alzheimer Disease (AD) dementia. This is done by looking at participants: thinking and memory (cognition), everyday activities and sleep, AD symptoms, physical activity, irritability or anxiety. The study is expected to last approximately 26 weeks and may include up to 14 visits.
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
04/17/2025
Locations: CenExel iResearch, LLC, Savannah, Georgia
Conditions: Alzheimer Disease
Register for Updates
Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)
NCT05531526
Recruiting
This AR1001-ADP3-US01 protocol is a double-blind, randomized, placebo-controlled, multi- center, parallel-group comparison pivotal Phase 3 study to evaluate the efficacy and safety of AR1001 for the treatment of participants with early AD.
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
04/16/2025
Locations: iResearch, Savannah, Georgia
Conditions: Alzheimer Disease
Register for Updates
Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry
NCT05999084
Recruiting
The purpose of this registry is to compile information on patients who are receiving FDA-approved anti-amyloid mAbs in the course of their clinic visits in the Emory Cognitive Neurology Clinic and in Georgia Memory Net Memory Assessment Clinics.
Gender:
ALL
Ages:
Between 50 years and 90 years
Trial Updated:
03/06/2025
Locations: Georgia Memory Net Memory Assessment Clinic - Savannah, Savannah, Georgia
Conditions: Alzheimer Disease
Register for Updates